<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Epigenetics involved in coronavirus infection and their therapeutic control</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th colspan="2">Epigenetic drug target</th>
    <th colspan="2">Antagonism “inhibitors”</th>
    <th>Potential outcome</th>
    <th>Combination therapy(few require clinical validation)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="5">HDAC</td>
    <td rowspan="3">Pan-HDAC class I and II</td>
    <td colspan="2">VPA</td>
    <td>Affecting inflammatory functions and interferon response [
     <xref ref-type="bibr" rid="CR45">45</xref>].
    </td>
    <td>
     <p>VPA + antivirals (remdesivir, ribavirin, favipiravir, galidesivir) or (rapamycin, selumetinib, trametinib)</p>
     <p>or prostatin</p>
    </td>
   </tr>
   <tr>
    <td colspan="2">TSA</td>
    <td>Reduced pro-inflammatory mediator’s production and increased IL-10 production [
     <xref ref-type="bibr" rid="CR55">55</xref>].
    </td>
    <td>
     <p>TSA + antivirals or</p>
     <p>(rapamycin, selumetinib, trametinib)</p>
    </td>
   </tr>
   <tr>
    <td colspan="2">Vorinostat (SAHA)</td>
    <td>Diminished genomes initiating gene replication, and induced the expression of cellular proteins responsible for viral inhibition [
     <xref ref-type="bibr" rid="CR57">57</xref>].
    </td>
    <td>SAHA + antivirals or (rapamycin, selumetinib, trametinib) or prostatin or BIX-01294 or DZNep</td>
   </tr>
   <tr>
    <td rowspan="2">All HDAC classes including class I, II, and IV</td>
    <td colspan="2">Panobinostat</td>
    <td>Affecting EGFR/HER2 signaling, MAPK signaling, PI3K-Akt, and NFκB pathway [
     <xref ref-type="bibr" rid="CR58">58</xref>].
    </td>
    <td>Panobinostat + antivirals or (rapamycin, selumetinib, trametinib)</td>
   </tr>
   <tr>
    <td colspan="2">Belinostat and domatinostat</td>
    <td>Enhanced TGF-β expression [
     <xref ref-type="bibr" rid="CR58">58</xref>].
    </td>
    <td>Belinostat or domatinostat + antivirals or (rapamycin, selumetinib, trametinib)</td>
   </tr>
   <tr>
    <td rowspan="3">HKMT</td>
    <td>Pan-HKMT EZH2</td>
    <td colspan="2">DZNep</td>
    <td>Attained cellular antiviral state and reduced viral yields [
     <xref ref-type="bibr" rid="CR57">57</xref>].
    </td>
    <td>DZNep + vorinostat</td>
   </tr>
   <tr>
    <td>HKMT G9a</td>
    <td colspan="2">BIX-01294</td>
    <td>Enhancing antiviral state [
     <xref ref-type="bibr" rid="CR57">57</xref>].
    </td>
    <td>BIX-01294 + vorinostat</td>
   </tr>
   <tr>
    <td>HMT Suv39H1</td>
    <td colspan="2">Chaetocin</td>
    <td>Permanent cell cycle arrest and RNA transcript blockage [
     <xref ref-type="bibr" rid="CR59">59</xref>].
    </td>
    <td/>
   </tr>
   <tr>
    <td colspan="2">HAT</td>
    <td colspan="2">Anacardic acid, MG149, C646</td>
    <td>Suppressed IL-6 levels [
     <xref ref-type="bibr" rid="CR60">60</xref>, 
     <xref ref-type="bibr" rid="CR61">61</xref>].
    </td>
    <td/>
   </tr>
   <tr>
    <td rowspan="3" colspan="2">DNMT</td>
    <td colspan="2">Resveratrol</td>
    <td>Down-regulation of apoptosis, decrease in (N) protein expression, and RNA viral replication antagonism [
     <xref ref-type="bibr" rid="CR51">51</xref>].
    </td>
    <td/>
   </tr>
   <tr>
    <td colspan="2">
     <p>Decitabine</p>
     <p>(5-azadC)</p>
    </td>
    <td>Counteracting hyper-inflammation: lowering pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and chemokines, inducing IL-10 marker and TGF-β [
     <xref ref-type="bibr" rid="CR58">58</xref>].
    </td>
    <td>5-azadC + antivirals or (rapamycin, selumetinib, trametinib)</td>
   </tr>
   <tr>
    <td colspan="2">Azacitidine</td>
    <td>Viral mimicry [
     <xref ref-type="bibr" rid="CR62">62</xref>].
    </td>
    <td>Azacitidine + antivirals or (rapamycin, selumetinib, trametinib)</td>
   </tr>
   <tr>
    <td rowspan="2" colspan="2">BET proteins (BRD4)</td>
    <td>Clinical</td>
    <td>ABBV-744, CPI-0610, RVX-208</td>
    <td rowspan="2">BRD4 inhibition boosts a potential innate immune response, blocks viral attachment, inducts DNA damage response (DDR), decreases viral replication, and arrests cell-cycle with no apoptotic signs [
     <xref ref-type="bibr" rid="CR63">63</xref>].
    </td>
    <td rowspan="2"/>
   </tr>
   <tr>
    <td>Preclinical</td>
    <td>dBET6, JQ-1, MZ1</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
